14.03 GLYCOMACROPEPTIDE AND ESSENTIAL AMINO ACID WITH

VITAMINS AND MINERALS

oral liquid: powder for, 30 x 49 g,

Camino Pro® Bettermilk, Cortex Health Pty Ltd.

# Purpose of Application

* 1. To advise of an upgrade in pack size from 28 sachets to 30 sachets per pack.

# Requested listing

* 1. The submission requested restrictions in line with comparable products.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Name, Restriction,Manner of administration and form | Max.Qty | №.ofRpts | Dispensed Price for Max. Qty | Proprietary Name and Manufacturer |
| GLYCOMACROPEPTIDE AND ESSENTIAL AMINO ACIDS WITH VITAMINS AND MINERALS glycomacropeptide and essential amino acids with vitamins and minerals containing 15 g protein oral liquid: powder for, 30 x 49 g | 4 | 5 | $''''''''''''''''''''' | Camino Pro Bettermilk® | QH |
| **Category /Program** | GENERAL – General Schedule (Code GE) |
| **Prescriber type:** | [ ] Dental [x] Medical Practitioners [x] Nurse practitioners [ ] Optometrists [ ] Midwives |
| **Episodicity:** | - |
| **Severity:** | - |
| **Condition:** | Phenylketonuria |
| **PBS Indication:** | Phenylketonuria |
| **Treatment phase:** | - |
| **Restriction Level / Method:** | [x] Restricted benefit[ ] Authority Required - In Writing[ ] Authority Required - Telephone[ ] Authority Required – Emergency[ ] Authority Required - Electronic[ ] Streamlined |

# Consideration of the evidence

## Sponsor hearing

* 1. There was no hearing for this item as it was a minor submission.

## Consumer comments

* 1. The PBAC noted that no consumer comments were received for this item.

## Estimated PBS usage & financial implications

* 1. The dispensed price for maximum quantity (DPMQ) increase from $''''''''''''''''''' (28 pack) to $''''''''''''''''''' is based on same price per gram of protein equivalent as current pack. AEMP is correct. However, DPMQ in submission is incorrect due to rounding errors. The correct DPMQ is $'''''''''''''''''''''.
	2. The submission states the change to a slightly larger pack size would not be expected to result in a meaningful net financial change in cost to the PBS. The submission does not quantify this change.

# PBAC Outcome

* 1. The PBAC noted the Nutritional Products Working Party had no objection to the increased pack size of 30 sachets per pack at the same price per gram of protein of Camino Pro Bettermilk®.
	2. The PBAC noted that US manufacturer Cambrooke Therapeutics had recently replaced the 28 sachet box with a 30 sachet box in the US and Europe and is planning to cease manufacture of the 28 sachet pack size. This product is prescribed by number of sachets per day, and so the increased pack size will result in slightly fewer prescriptions needed.
	3. The PBAC also noted that the nutritional changes to the product since the initial listing but considered the changes were not clinically significant.
	4. The PBAC therefore accepted the changes as requested.

## Outcome:

Recommended

# Recommended listing

* 1. Amend existing listing as follows:

|  |  |  |  |
| --- | --- | --- | --- |
| Name, Restriction,Manner of administration and form | Max.Qty | №.ofRpts | Proprietary Name and Manufacturer |
| GLYCOMACROPEPTIDE AND ESSENTIAL AMINO ACIDS WITH VITAMINS AND MINERALS glycomacropeptide and essential amino acids with vitamins and minerals containing 15 g protein oral liquid: powder for, 30 x 49 g | 4 | 5 | Camino Pro Bettermilk® | QH |
| **Category / Program** | GENERAL – General Schedule (Code GE) |
| **Prescriber type:** | [ ] Dental [x] Medical Practitioners [x] Nurse practitioners [ ] Optometrists [ ] Midwives |
| **Episodicity:** | - |
| **Severity:** | - |
| **Condition:** | Phenylketonuria |
| **PBS Indication:** | Phenylketonuria |
| **Treatment phase:** | - |
| **Restriction Level / Method:** | [x] Restricted benefit[ ] Authority Required - In Writing[ ] Authority Required - Telephone[ ] Authority Required – Emergency[ ] Authority Required - Electronic[ ] Streamlined |

# Context for Decision

The PBAC helps decide whether and, if so, how medicines should be subsidised in Australia. It considers submissions in this context. A PBAC decision not to recommend listing or not to recommend changing a listing does not represent a final PBAC view about the merits of the medicine. A company can resubmit to the PBAC or seek independent review of the PBAC decision.

# Sponsor’s Comment

The sponsor had no comment.